Humaneva

Humaneva Inc. is a provider of integrated clinical trial solutions, operating through its subsidiaries Pratia, Kapadi, and Hyggio. The company offers a comprehensive approach to clinical research, combining Site Management Organization (SMO), Contract Research Organization (CRO), and technology services. Humaneva's SMO division, Pratia, operates the largest network of clinical trial centers in Europe and the world's largest oncology network of its kind. Kapadi, the CRO arm, specializes in biotechnological oncology projects, including research on new gene and cell therapies. Hyggio, the technology division, provides comprehensive software for conducting clinical trials, integrating Data Analytics, Data Warehouse, eSource, CTMS, and Remote Monitoring systems.

The company distinguishes itself through direct patient access, a strong focus on oncology, advanced data management capabilities, and proprietary technology that integrates clinical trial centers, sponsors, and CROs. This approach enhances project efficiency by streamlining processes and reducing indirect tasks, ultimately lowering costs associated with molecule development for trial sponsors. Humaneva operated over 90 dedicated and integrated Clinical Trial Centers as of September 2024. The company's technology offerings focus on eSource solutions, data integration, and analytics, aiming to broaden access to clinical research as a care option worldwide. In September 2024, Viking Global Investors, a US-based global investment firm, acquired a minority stake in Humaneva for USD 50 million, with an option to invest an additional USD 50 million within one year.

Key customers and partnerships

Humaneva's customer base primarily consists of trial sponsors in the biotechnology and pharmaceutical industries, with a particular emphasis on oncology research. The company's services address one of the major challenges in the industry: effectively recruiting the right patients at the right time and place. Humaneva's expansion plans indicate a focus on serving clients in the US and APAC regions, which are recognized as hubs for advanced clinical trial activities. The company's partnership with Viking Global Investors in September 2024 is expected to support its long-term growth strategy and facilitate expansion into these markets.